Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere Given SFDA Approval of Anti-Nausea Drug

publication date: Aug 12, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharmaceutical Group (先声药业) reported that its China subsidiary, Simcere Dongyuan Pharmaceutical Co., was granted SFDA approval to manufacture and market Palonosetron material and injections. Palonosetron is given to prevent the nausea and vomiting side effects of chemotherapy. Simcere, which focuses on branded generics, already markets four other drugs that treat cancer. More details...

Stock Symbol: (NYSE: SCR)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners